INDIAN DRUGS (MEDICINES)
India is one of the most populated & progressive country with people of different economic status like rich, middle & poor. Due to changing lifestyle and environment there is prevalence of many diseases but at the same time remedy for it is also available.
Since some medicines are expensive not within the reach of common man especially innovative / research molecules which is affecting the health of Indian patients, Indian government is planning to provide these medicines at economical prices for which they are making necessary changes in their constitution so that these molecules are available with Indian brands at 5% -10% of the cost of innovative / research medicines
Government through NPPA(National Pharmaceutical Pricing Authority) is keeping close & constant watch on overpricing & overprofiting by any company. If they sell their product with high profit margins compared to their actual manufacturing cost, government is taking action against them & those companies are bound to reduce rates & sell at reasonable prices.
Healthcare has become one of the key priorities of the Indian government & it has launched new policies & programmes to boost local access & affordability to quality healthcare to all human beings.
- Union health ministry is drafting guidelines towards enhancement of good manufacturing practice (GMP) to align India’s specific standards with global regulations for better product quality.
- Drug Controller General of India (DCGI) has submitted a proposal to health ministry to mandate upgradation of schedule ‘M’ drug manufacturing units to WHO – GMP level under the purview of drug rules towards good manufacturing practices adopted globally.
- Implementing DPCO for majority life saving drugs well within the reach of common man
- DCGI gives permission to Indian companies to manufacture generic version of innovator brands with equivalent quality under provision of compulsory license to take care of Indian patients
- DCGI also gives permission to Indian companies without violating patient law ie.after 3 years of patency to manufacture if the requirement of patency is not maintained by innovator in India.
With the above steps by Indian government to boost Pharma industrial sector, global Pharma market also looks to India as a prospective because of following limitations,
- Higher R & D costs
- Dry pipelines for new drugs
- Pressure from payers & providers for reducing Healthcare costs.
On the other hand
- India has a phramceutical industry of its own & is likely to become a competitor to global Pharma in some key areas & a potential patner in others
- Indian companies are amongst the world leaders in the production of generic & vaccines, which is likely to take a large role on world stage & potential patner with global Pharma companies.
- Indian pharmaceutical firms focus on automation & work culture to improve quality standards to ensure their process are in line with expectation, set by
- Indian pharma companies has considerable manufacturing expertise & also started entering into the realm of R & D as well as clinical trials as it is cost-effective compared to other developed countries
b. European Medicine Agency (EMA)
c. U. K. Medicines & Healthcare products Regulatory Agency (MHRA)
d. European directorate for Quality Medicines (EDQM)
All these factors makes India as a Hub of Medical / Pharmaceutical Business with Indian pharmaceutical companies manufacturing medicines with international quality standards meeting the needs of Indian as well as global patients with an edge over multinationals in terms of economic costing.
Thus Indian drugs will make a significant contribution to humanity by improving global health.
Shubham Pharmaceutical focuses on impacting humans with affordable & high quality medicines crossing all political boundaries ensuring a true global reach.